Moderna's Omicron-containing bivalent vaccine get approval in Australia as booster shot
hapabapa/iStock Editorial via Getty Images


Australia's Therapeutic Goods Administration granted provisional approval to Moderna's (NASDAQ:MRNA) Omicron-containing bivalent booster vaccine mRNA-1273.214 for people 18 years of age and older.
Moderna has already received approval for mRNA-1273.214 in the U.K. and Switzerland.
The company said in an Aug. 30 press release that Spikevax Bivalent Original/Omicron is a next-generation bivalent vaccine that contains 25 Âµg of mRNA-1273 (Spikevax) and 25 Âµg of a vaccine candidate targeting the Omicron variant of concern (BA.1).

The decision was backed by data from a phase 2/3 trial in which mRNA-1273.214 met all main goals, including superior neutralizing antibody response against Omicron (BA.1) when compared to a 50 Âµg booster dose of mRNA-1273 in previously uninfected people.
Moderna (MRNA) expects to supply mRNA-1273.214 to Australia in September.
MRNA +1.27% to $139 premarket Aug. 30